Perhexiline Maleate Induced Cirrhosis

No abstract is available for this paper.

• Publication year

  1983

• Venue

  Pathology (Sydney)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/00313028309084714PMID 6888970
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liver disease induced by perhexiline maleate.

  1981cited by this paper
• Liver disease induced by perhexiline maleate.

  1981cited by this paper
• Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid).

  1980cited by this paper
• Toxic polyneuritis and toxic hepatitis related to long-term perhexiline maleate therapy.

  1980cited by this paper
• Hepatotoxicity following treatment with perhexiline maleate.

  1980cited by this paper
• Perhexiline maleate-induced cirrhosis.

  1979cited by this paper
• Long‐Term Safety of Perhexiline Maleate

  1979cited by this paper
• Liver damage due to perhexiline maleate.

  1979cited by this paper
• Liver damage associated with perhexiline maleate.

  1979cited by this paper
• Perhexiline maleate-induced hepatitis.

  1978cited by this paper
• Liver damage after perhexiline maleate.

  1977cited by this paper
• [Hepatic overload of gangliosides after perhexiline maleate. Morphological and biochemical course (author's transl)].

  1977cited by this paper
• Liver ganglioside storage after perhexiline maleate.

  1977cited by this paper
• Drug-induced chronic liver disease.

  1977cited by this paper
• Liver damage after perhexiline maleate.

  1977cited by this paper
• LIVER DURING PERHEXIUNE HYPOGLYCÆMIA

  1977cited by this paper
• Proximal myopathy after perhexiline maleate treatment.

  1977cited by this paper
• Liver during perhexiline hypoglycaemia.

  1977cited by this paper
• Report of a multicentre monitored release study of perhexiline maleate in the prevention of angina pectoris.

  1976cited by this paper
• Long-term perhexiline maleate and liver function.

  1976cited by this paper
• Report of a Multicentre * Monitored Release Study of Perhexiline Maleate in the Prevention of Angina Pectoris

  1976cited by this paper
• [Perhexiline maleate in the treatment of angina pectoris].

  1976cited by this paper
• Insulin rather than glucose homoeostasis in the pathophysiology of diabetes.

  1976cited by this paper
• Prevention of postoperative deep vein thrombosis by leg bandaging and oxyphenbutazone.

  1976cited by this paper
• Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine.

  1975cited by this paper
• [Letter: Hypoglycemia and perhexilline].

  1974cited by this paper
• Letter: Open university medical school.

  1974cited by this paper
• Proceedings: Assessment of safety data from patients on short and long-term perhexiline therapy.

  1973cited by this paper
• Proceedings: Clinical experience with perhexiline maleate in forty-six patients with angina.

  1973cited by this paper
• Proceedings: Long-term assessment of perhexiline maleate in angina pectoris.

  1973cited by this paper
• Proceedings: Clinical experience with perhexiline maleate in forty-six patients with angina.

  1973cited by this paper
• Proceedings: Assessment of safety data from patients on short and long-term perhexiline therapy.

  1973cited by this paper
• Natural history of alcoholic hepatitis. 3. Histological changes.

  1972cited by this paper
• Clinical Evaluation of Perhexiline Maleate in Patients with Angina Pectoris

  1971cited by this paper
• Perhexilene maleate in treatment of angina pectoris.

  1971cited by this paper
• GENETIC STUDIES BY RECORD LINKAGE.

  1965cited by this paper
• DEATHS IN THE COMMUNITY.

  1964cited by this paper
• Electrocardiographs in General Practice

  1961cited by this paper

• Mutagenic, Acute, and Subchronic Toxicity Studies of the Hesperetin-7-Glucoside–β-Cyclodextrin Inclusion Complex

  2022cites this paper
• Medikamentös-toxischer Leberschaden (DILI)

  2020cites this paper
• Integrating In Vitro, Modeling, and In Vivo Approaches to Investigate Warfarin Bioequivalence

  2017cites this paper
• Emerging drugs for the treatment of angina pectoris

  2016cites this paper
• Drug-induced fatty liver disease: An overview of pathogenesis and management.

  2015cites this paper
• Nonalcoholic fatty liver

  2013cites this paper
• Drug-induced steatohepatitis.

  2013cites this paper
• Current Perspectives in Hepatology

  2012cites this paper
• Central role of mitochondria in drug-induced liver injury

  2012cites this paper
• Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver.

  2011cites this paper
• Mécanismes de l'hépatotoxicité médicamenteuse

  2010cites this paper
• Histological patterns in drug-induced liver disease

  2009cites this paper
• La stéatohépatite non alcoolique

  2008cites this paper
• In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.

  2007cites this paper
• Mallory Body Formation Runs Parallel to γ‐Glutamyl Transferase Induction in Hepatocytes of Griseofulvin‐Fed Mice

  2007cites this paper
• Adaptation of an In Vitro Phospholipidosis Assay to an Automated Image Analysis System

  2007cites this paper
• Potential of metabolic agents as adjunct therapies in heart failure.

  2007cites this paper
• Pathogenesis and management issues for non-alcoholic fatty liver disease.

  2007cites this paper
• Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells.

  2006influential citation
• Drug-induced phospholipidosis: issues and future directions

  2006cites this paper
• Studies on the metabolism of perhexiline in man

  2006cites this paper
• The natural history of non-alcoholic fatty liver disease

  2006cites this paper
• Modification of myocardial substrate use as a therapy for heart failure

  2006cites this paper
• Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity

  2005cites this paper
• A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.

  2005cites this paper
• NASH

  2003cites this paper
• Polymorphic hydroxylation of perhexiline in vitro.

  2003cites this paper
• De Novo Non‐Alcoholic Fatty Liver Disease Following Orthotopic Liver Transplantation

  2003cites this paper
• [Non alcoholic steatohepatitis: a multifactorial, frequent, paucysymptomatic liver disease with a fibrotic outcome].

  2002cites this paper
• Drugs and Steatohepatitis

  2002cites this paper
• Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes

  2001cites this paper
• Etiopathogenesis of Nonalcoholic Steatohepatitis

  2001cites this paper
• Subacute Severe Steatohepatitis During Prednisolone Therapy for Systemic Lupus Erythematosis

  1999cites this paper
• Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance.

  1998cites this paper
• Chronic hepatitis infected with hepatitis GB virus type C/hepatitis G virus presenting as non-alcoholic steatohepatitis.

  1997cites this paper
• Method for the analysis of perhexiline and its hydroxy metabolite in plasma using high-performance liquid chromatography with precolumn derivatization.

  1997cites this paper
• Stimulatory effect of perhexiline maleate on the basal and LHRH-stimulated luteinizing hormone release from rat pituitary cell aggregates in vitro.

  1995cites this paper
• Inhibition by perhexiline of oxidative phosphorylation and the β‐oxidation of fatty acids: Possible role in pseudoalcoholic liver lesions

  1994cites this paper
• The mallory body: Theories on development and pathological significance (part 2 of a literature survey)

  1994cites this paper
• The mallory body: Morphological, clinical and experimental studies (part 1 of a literature survey)

  1994cites this paper
• Alveolar proteinosis and phospholipidoses of the lungs.

  1991cites this paper
• Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype?

  1990cites this paper
• The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years

  1990cites this paper
• Hepatotoxicity Associated with Amiodarone Therapy

  1989cites this paper
• PERHEXILENE: EFFECTS ON HEPATIC LYSOSOMAL FUNCTION IN RATS

  1989cites this paper
• Effects of perhexiline maleate on asialo-orosomucoid receptor endocytosis and recycling in HTC cells.

  1989cites this paper
• Amiodarone‐induced hepatic phospholipidosis: Correlation of morphological and biochemical findings in an animal model

  1988cites this paper
• Pharmacogenetic aspects of biological variability

  1988cites this paper
• Liver disease in the alcoholic.

  1986cites this paper
• Nonalcoholic fatty liver disease.

  1986cites this paper
• Drug-induced liver injury in liver biopsies of the years 1981 and 1983, their prevalence and type of presentation.

  1985cites this paper
• Antianginal and β-adrenoceptor blocking drugs

  1985cites this paper
• Impaired oxidation of debrisoquine in patients with perhexiline liver injury.

  1984cites this paper
• Pulmonary and generalized lysosomal storage induced by amphiphilic drugs.

  1984cites this paper
• Polymorphic hydroxylation of perhexiline maleate in man.

  1984cites this paper
• Fasting in obesity

  1982cites this paper
• Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.

  1982cites this paper
• Drugs and Liver Disease: A Tabular Compilation of Drugs and the Histopathological Changes That Can Occur in the Liver

  1982cites this paper
• Pathology of Alcoholic Liver Diseases

  1981cites this paper